[go: up one dir, main page]

WO1997034594A3 - Use of allosteric haemoglobin modifier for treating solid tumors and inhibiting tumor metastases - Google Patents

Use of allosteric haemoglobin modifier for treating solid tumors and inhibiting tumor metastases Download PDF

Info

Publication number
WO1997034594A3
WO1997034594A3 PCT/US1997/003465 US9703465W WO9734594A3 WO 1997034594 A3 WO1997034594 A3 WO 1997034594A3 US 9703465 W US9703465 W US 9703465W WO 9734594 A3 WO9734594 A3 WO 9734594A3
Authority
WO
WIPO (PCT)
Prior art keywords
allosteric
haemoglobin
modifier
solid tumors
inhibiting tumor
Prior art date
Application number
PCT/US1997/003465
Other languages
French (fr)
Other versions
WO1997034594A2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to AU26575/97A priority Critical patent/AU2657597A/en
Publication of WO1997034594A2 publication Critical patent/WO1997034594A2/en
Publication of WO1997034594A3 publication Critical patent/WO1997034594A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for treating neoplastic growth and/or metastases is described. This involves using allosteric effectors, preferably fibric acid derivatives. In one embodiment, these compounds are used in a subject having a tumor experiencing rapid growth and at risk for metastases. In another embodiment, these compounds are used with a second antineoplastic agent such as radiation or a chemotherapeutic agent.
PCT/US1997/003465 1996-03-21 1997-03-21 Use of allosteric haemoglobin modifier for treating solid tumors and inhibiting tumor metastases WO1997034594A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU26575/97A AU2657597A (en) 1996-03-21 1997-03-21 Use of allosteric haemoglobin modifier for treating solid tumors and inhibiting tumor metastases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1381896P 1996-03-21 1996-03-21
US60/013,818 1996-03-21

Publications (2)

Publication Number Publication Date
WO1997034594A2 WO1997034594A2 (en) 1997-09-25
WO1997034594A3 true WO1997034594A3 (en) 1997-12-24

Family

ID=21761928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/003465 WO1997034594A2 (en) 1996-03-21 1997-03-21 Use of allosteric haemoglobin modifier for treating solid tumors and inhibiting tumor metastases

Country Status (2)

Country Link
AU (1) AU2657597A (en)
WO (1) WO1997034594A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439298A1 (en) 2001-02-23 2002-09-06 Allos Therapeutics, Inc. Methods and reagents to acquire mri signals and images
WO2005102305A2 (en) 2004-04-22 2005-11-03 Allos Therapeutics, Inc. Compositions of allosteric hemoglobin modifiers and methods of making the same
WO2015100235A1 (en) * 2013-12-27 2015-07-02 Virginia Commonwealth University Allosteric hemoglobin modifiers with nitric oxide releasing moiety

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020335A1 (en) * 1991-05-20 1992-11-26 Center For Innovative Technology Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5432191A (en) * 1990-02-12 1995-07-11 The Center For Innovative Technology Allosteric hemoglobin modifiers to decrease oxygen affinity in blood

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432191A (en) * 1990-02-12 1995-07-11 The Center For Innovative Technology Allosteric hemoglobin modifiers to decrease oxygen affinity in blood
WO1992020335A1 (en) * 1991-05-20 1992-11-26 Center For Innovative Technology Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CALAIS ET AL: "In situ tumour radiosensitization induce by ....", RADIOTHERAPY AND ONCOLOGY, vol. 22, 1991, pages 99 - 103, XP002039429 *
KHANDELWAL ET AL: "Enhanced oxygenation in vivo .....", AM. J. PHYSIOL., vol. 265, 1993, pages H1450 - 53, XP002039428 *
TEICHER ET AL: "RSR13: Effects on tumor....", DRUG DEV. RES., vol. 38, May 1996 (1996-05-01), pages 1 - 11, XP002039430 *

Also Published As

Publication number Publication date
WO1997034594A2 (en) 1997-09-25
AU2657597A (en) 1997-10-10

Similar Documents

Publication Publication Date Title
WO1999043355A3 (en) Formulations containing oxaliplatin
CA2227205A1 (en) Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
CA2336624A1 (en) Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
WO1998051294A3 (en) Method and composition for treating cancers
WO1997033551A3 (en) Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
AU3102595A (en) Retractors, tool, and method for direct access endoscopic surgery
NO986089D0 (en) Methods and preparations for the treatment of tumors, tumor-related diseases and o
CA2199117A1 (en) Compounds and methods for the treatment of cancer
WO2001028494A3 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
NO974694L (en) Pharmaceutical preparation containing N-phosphonoglycine derivatives to inhibit cancer and virus growth
AU7629694A (en) Compositions for treating corns, calluses and warts
GR940100307A (en) Method for treating seeds using phosphoric acid or one of its salts.
CA2217953A1 (en) A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancers
AU1233701A (en) Methods and compositions for treating atheroma, tumors and other neoplastic tissue
FI844593A7 (en) Treatment of hypertension, compounds and combinations for antihypertensive and diuresis.
WO2002060436A8 (en) Use of fredericamycin a and its derivatives in the treatment of pin1-associated states
WO1997034594A3 (en) Use of allosteric haemoglobin modifier for treating solid tumors and inhibiting tumor metastases
AU5241499A (en) Method of treating cancer in patients having a deficiency in p53 tumor suppressor gene
AU6580494A (en) Use of clioquinol for treating helicobacter, including (h. pylori), infections and related diseases
EP0127124A3 (en) Compounds for treating hypertension
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
ZA918116B (en) Inhibitors for the formation of tumor necrosis factor,processes for the preparation thereof and the use thereof
WO2000004153A3 (en) Repression of cell transformation with human pea3
AU8083682A (en) Agent for treating allergic disease, immunuty complex diseaseand tumor
CA2297149A1 (en) 13-deoxyanthracycline derivatives for treating cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 41/97 UNDER INID (81) "DESIGNATED STATES", ADD "CN, KP, MX, NO, PL"

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97533499

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA